By Michele Evans / NYweeklyRecord.com / Date: 10/2/2026
Category: Consumer Protection / Health Care / Accountability / New York State
NEW YORK CITY, NY – New Yorkers who paid for certain generic prescription drugs can now seek money from a $400 million settlement resolving price-fixing claims against Sandoz Inc. and Fougera Pharmaceuticals Inc.
Attorney General Letitia James announced the settlement Thursday as part of a bipartisan coalition of 48 attorneys general. The states accused Sandoz and other drug manufacturers of coordinating prices, limiting competition and rigging bids for more than 100 generic medications.
The lawsuits remain allegations against companies that have not resolved their cases. The Sandoz agreement settles claims against that company and requires payment and compliance reforms. It is not a court verdict establishing liability against every company named in the broader litigation.
The drugs at issue include antibiotics, antidepressants, contraceptives and treatments for diabetes, cancer, epilepsy, multiple sclerosis, HIV and ADHD. According to the attorney general’s office, some coordinated price increases exceeded 1,000 percent.
Consumers may be eligible if they purchased a generic prescription drug listed on the settlement website between May 2009 and December 2019. Claims must be submitted by March 8, 2027. Eligibility information and the claim form are available at AGGenericDrugs.com.
Sandoz will pay $320,560,180 plus interest over seven years, bringing the total to $400 million. The money will be distributed among affected consumers in the participating states and territories. The public materials do not state how much an individual claimant will receive.
The settlement also requires changes inside the company. Sandoz must establish an antitrust compliance program, provide annual training to sales and management employees and hire a chief compliance officer responsible for enforcing competition rules.
The case grew from three multistate lawsuits against major generic-drug manufacturers and executives. The first complaint named 18 companies, two executives and 15 drugs. A second case filed in 2019 targeted Teva Pharmaceuticals and 19 other manufacturers. A third case covers 80 primarily topical generic drugs and is scheduled to be tried first.
State prosecutors allege that industry executives built a network of contacts through dinners, lunches, golf outings, phone calls, emails and text messages. The complaints say participants used phrases such as “fair share” and “responsible competitor” while arranging deals that reduced competition.
Those allegations matter because generic medicines are supposed to create price pressure by offering lower-cost alternatives to brand-name drugs. When competitors coordinate instead of competing, patients, insurers and public health programs can all pay more.
This settlement follows agreements with several other manufacturers. New York and the coalition secured more than $29 million from Glenmark Pharmaceuticals in July and $17 million from Lannett and Bausch in February. Additional litigation continues.
For consumers, the accountability test is practical. People who paid inflated prices must be able to identify covered medications, file claims without unnecessary barriers and receive a fair share of the settlement. State officials must also enforce the promised compliance reforms while the remaining cases move forward.
Anyone who believes they qualify can review the drug list and submit a claim at AGGenericDrugs.com, call 1-866-290-0182 or email info@aggenericdrugs.com. The deadline is March 8, 2027.
Sources
New York Attorney General: $400 Million Sandoz Generic-Drug Settlement
Leave a Reply